Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units

Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units is offered by Harvest, a leading player in the field of passive investments.

The total expense ratio of Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units is 0.6%, which means that investors pay 60 CNY per 10,000 CNY in investment capital annually.

The ETF is listed in CNY.

European investors may incur additional costs for currency exchange and transaction fees.

No, Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units does not comply with the EU UCITS investor protection directives.

Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units tracks the performance of the CSI Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Net.

Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units is domiciled in CN.

The fund was launched on 7/30/2025.

The Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units mainly invests in Healthcare companies.

The NAV of Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units amounts to 901,548.27 CNY.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.